title: Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
abstract: Polysorbate 80 coated temozolomide-loaded PLGA-based superparamagnetic nanoparticles (P80-TMZ/SPIO-NPs) were successfully synthesized and characterized as drug carriers and diagnosis agent for malignant brain glioma. The mean size of P80-TMZ/SPIO-NPs was 220 nm with narrow hydrodynamic particle size distribution. The superparamagnetic characteristic of P80-TMZ/SPIO-NPs was proved by vibration simple magnetometer. P80-TMZ/SPIO-NPs exhibited high drug loading and encapsulation efficiency as well as good sustained drug release performance for 15 days. MTT assay demonstrated the antiproliferative effect of P80-TMZ/SPIO-NPs for C6 glioma cells. Significant cellular uptake of P80-TMZ/SPIO-NPs was evaluated in C6 glioma cells by fluorescence microscopy, Prussian blue staining, and atomic absorption spectrophotometer (AAS) for qualitative and quantitative study, respectively. MRI scanning analyses in vitro indicated that P80-TMZ/SPIO-NPs could be used as a good MRI contrast agent. Polysorbate 80 coated temozolomide-loaded PLGA-based superparamagnetic nanoparticles could be able to promise a multifunctional theragnostic carrier of brain cancer.
authors.affiliation: School of Materials Science and Engineering, South China University of Technology, Guangzhou, Guangdong 510640, China.
authors.forename: You
authors.initials: Y
authors.lastname: Ling
authors.forename: Kun
authors.initials: K
authors.lastname: Wei
authors.forename: Fen
authors.initials: F
authors.lastname: Zou
authors.forename: Shizheng
authors.initials: S
authors.lastname: Zhong
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D001692:Biological Transport; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003287:Contrast Media / Q000737:chemistry / Q000378:metabolism; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D005910:Glioma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D007700:Kinetics; D019344:Lactic Acid / Q000737:chemistry*; D008027:Light; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D046529:Microscopy, Electron, Transmission; D008856:Microscopy, Fluorescence; D050997:Nanomedicine; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011136:Polysorbates / Q000737:chemistry; D051381:Rats; D012542:Scattering, Radiation; D012995:Solubility; D013054:Spectrophotometry, Atomic; D013678:Technology, Pharmaceutical / Q000379:methods; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003287:Contrast Media; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D058185:Magnetite Nanoparticles; D011136:Polysorbates; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D003606:Dacarbazine; D000077204:Temozolomide